[COMPANY LOGO OMITTED]
CONTACT:
- --------
Kara Stancell, Investor Relations & Corporate Communications, (602) 808-3854
MEDICIS REPORTS THIRD QUARTER FISCAL 2005 FINANCIAL RESULTS
SCOTTSDALE, Arizona--April 20, 2005--Medicis (NYSE:MRX) today announced third
quarter fiscal 2005 net revenue growth of approximately 16% to $95.2 million
with net income of $24.3 million, or $0.37 per diluted share, absent a $5.0
million tax-effected special charge associated with a research and development
collaboration with aaiPharma, compared to third quarter fiscal 2004 revenues of
$81.8 million with net income of $20.7 million, or $0.31 per diluted share.
Including the $5.0 million tax-effected special charge associated with the
research and development collaboration, the Company reported Generally Accepted
Accounting Principles ("GAAP") net income of $19.4 million, or $0.30 per diluted
share for the third quarter of fiscal 2005. Diluted per share amounts are
calculated using the "if-converted" method of accounting in accordance with
GAAP.
Third quarter fiscal 2005 revenues increased primarily as a result of growth in
each product segment category. The revenue growth in the acne products category
was due primarily to an increase in sales of PLEXION(R) Cleansing Cloths. The
revenue growth in the non-acne products category was due primarily to the launch
of VANOS(TM). The revenue growth in the non-dermatological products category was
due primarily to the approval of AMMONUL(R), and the increase in contract
revenue associated with fees derived from authorized generics launched on the
Company's behalf. The Company includes revenue derived from authorized generics
in the non-dermatological products category. At the end of the third quarter,
the Company's core brands included DYNACIN(R), LOPROX(R), OMNICEF(R),
PLEXION(R), RESTYLANE(R), TRIAZ(R) and VANOS(TM). Additionally, the Company's
gross profit margin for third quarter fiscal 2005 increased to approximately 85%
from 84% for third quarter fiscal 2004 primarily due to a favorable change in
the Company's product mix.
For the nine months ended March 31, 2005, Medicis reported revenues of $276.4
million with net income of $68.4 million, or $1.03 per diluted share, absent a
$19.4 million tax-effected special charge associated with the SubQ(TM)
transaction, a $3.5 million tax-effected special charge associated with a
research and development collaboration with Ansata Therapeutics, and a $5.0
million tax-effected special charge associated with a research and development
collaboration with aaiPharma reported in the first nine months of fiscal 2005
totaling $27.8 million. Including the tax-effected special charges of $27.8
million reported in the nine months ended March 31, 2005, Medicis reported GAAP
net income of $40.6 million, or $0.64 per diluted share for the first nine
months of fiscal 2005.
Comparatively, in the first nine months of fiscal 2004, Medicis reported
revenues of $215.8 million with net income of $46.2 million, or $0.71 per
diluted share, absent a $37.5 million tax-effected loss associated with the
early extinguishment of debt and absent a $1.6 million tax-effected special
charge associated with a research and development collaboration reported in the
first nine months of fiscal 2004. Including the tax-effected special charges of
$37.5 million and $1.6 million reported in the nine months ended March 31, 2004,
(more)
Medicis reported GAAP net income of $7.1 million, or $0.12 per diluted share for
the first nine months of fiscal 2004.
For the first nine months of fiscal 2005, revenue increased approximately 28%
primarily as a result of growth in the Company's core brands. Additionally, the
Company's gross profit margin for the nine months ended fiscal 2005 increased to
approximately 85% from 84% over the nine months ended fiscal 2004 primarily due
to a favorable change in the Company's product mix.
Selling, general and administrative expenses for the third quarter of fiscal
2005 were $31.9 million, or approximately 33.5% of revenues, compared to $28.8
million, or approximately 35.2% of revenues, for the third quarter of fiscal
2004, a decrease as a percentage of revenues of approximately 2 percentage
points, primarily due to various operational efficiencies which resulted in less
spending.
Selling, general and administrative expenses for the first nine months of fiscal
2005 were $96.3 million, or approximately 34.9% of revenues compared to $87.9
million, or approximately 40.7% of revenues for the first nine months of fiscal
2004, a decrease as a percentage of revenues of approximately 6 percentage
points. Revenue growth outpaced the increase in selling, general and
administrative expenses primarily due to the investment spending behind the
RESTYLANE(R) launch incurred in the first nine months of fiscal 2004.
"We are pleased to announce another strong quarter characterized by continued
strength in the RESTYLANE(R) brand and two pipeline approvals," said Jonah
Shacknai, Chairman and Chief Executive Officer of Medicis. "In February, the
U.S. Food and Drug Administration approved the Class I corticosteroid,
VANOS(TM), and the Urea Cycle Disorder drug, AMMONUL(R). Both products enjoy
sound intellectual property protection and attractive market potential. As we
look to the fourth quarter and fiscal year-end, we anticipate a successful
VANOS(TM) launch to dermatologists, and continue advancing our sophisticated
research and development pipeline through its respective developmental stages.
Providing value to our shareholders and the physicians and patients we serve
remains our paramount focus."
The Company's current fiscal 2005 revenue guidance is approximately $376 million
with earnings per share guidance of $1.44.
At a September 29-30, 2004 meeting, the Emerging Issues Task Force ("EITF")
reached a conclusion that the accounting for contingently convertible debt
instruments, commonly referred to as "CoCos," should be included in diluted
earnings per share computations (if dilutive) regardless of whether the market
price trigger has been met, effective for periods ending after December 15,
2004.
As a result of the EITF's conclusion, third quarter fiscal 2005 and third
quarter fiscal 2004 diluted per share amounts and year-to-date diluted per share
amounts are calculated using the "if-converted" method of accounting in
accordance with GAAP regardless of whether the outstanding 2.5% Convertible
Senior Notes and 1.5% Convertible Senior Notes meet the criteria for conversion
and regardless of whether the bondholders actually convert their bonds into
shares. For the first nine months of fiscal 2004, the dilutive shares relative
to the convertible notes do not impact GAAP earnings per share, as they are
anti-dilutive.
At the time of this disclosure, Medicis believes these objectives are attainable
based upon information currently available to the Company. The Company's
business is subject to all risk factors outlined in the Company's most recent
annual report on Form 10-K and other filed documents with the Securities and
Exchange Commission. At the time of this release, the Company cannot, among
(more)
other things, assess the forthcoming results of the Company's research and
development projects and the risks associated with the FDA approval process,
risks associated with significant competition within the Company's industry, nor
can the Company validate its assumptions of the full impact on its business of
the approval of competitive generic versions of the Company's core brands, in
particular, the recent approval of a generic LOPROX(R) Cream or a substitutable
DYNACIN(R) Tablet form, and any future competitive product approvals that may
affect the Company's brands. Additionally, Medicis may acquire and/or license
products or technologies from third parties to enter into new strategic markets.
The Company periodically makes up-front, non-refundable payments to third
parties for research and development work which has been completed and
periodically makes additional non-refundable payments for the achievement of
various milestones. There can be no certainty in which periods these potential
payments could be made, nor if any payments such as these will be made at all.
The above estimated future guidance does not include the potential payments
associated with any such transactions.
Use of Non-GAAP Financial Information:
- --------------------------------------
The Company has provided non-GAAP financial information in this press release in
order to provide meaningful supplemental information regarding its operational
performance and to enhance its investors' overall understanding of its core
financial performance. Management measures the Company's performance using
non-GAAP financial measures such as those that are disclosed in this press
release. This information facilitates management's internal comparisons to the
Company's historical core operating results, comparisons to competitors' core
operating results and is a basis for financial decision making. Management
believes that Medicis' investors benefit from seeing the Company's results on
the same basis as management, in addition to the GAAP presentation. In our view,
the non-GAAP adjustments are informative to investors, allowing them to focus on
the ongoing operations and the core results of Medicis' business. Historically,
Medicis has reported similar non-GAAP information to its investors and believes
that the inclusion of comparative numbers provides consistency in the Company's
financial disclosures. This information is not in accordance with, or an
alternative for, information prepared using GAAP in the United States. It
excludes items, such as special charges for research and development, that may
have a material effect on the Company's net income and diluted net income per
common share calculated in accordance with GAAP. The Company excludes such
charges and the related tax benefits when analyzing its financial results as the
items are distinguishable events and have no impact to the Company's ongoing
results of operations. Management believes that by viewing the Company's results
of operations excluding these charges, investors are given an indication of the
ongoing results of the Company's operations.
Medicis is the leading independent specialty pharmaceutical company in the
United States focusing primarily on the treatment of dermatological and
podiatric conditions and aesthetics medicine. Medicis has leading branded
prescription products in a number of therapeutic categories, including acne,
eczema, fungal infections, hyperpigmentation, photoaging, psoriasis, rosacea,
seborrheic dermatitis and skin and skin-structure infections. The Company's
products have earned wide acceptance by both physicians and patients due to
their clinical effectiveness, high quality and cosmetic elegance.
The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R)
(minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R)
(sodium sulfacetamide/sulfur), TRIAZ(R) (benzoyl peroxide), LIDEX(R)
(fluocinonide) Cream, 0.05%, VANOS(TM) (fluocinonide) Cream, 0.1%, and
SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and
AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products
indicated in the treatment of Urea Cycle Disorder, and the over-the-counter
brand ESOTERICA(R). For more information about Medicis, please visit the
Company's website at www.medicis.com.
(more)
Except for historical information, this press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform Act. All
statements included in this press release that address activities, events or
developments that Medicis expects, believes or anticipates will or may occur in
the future are forward-looking statements. This includes earnings estimates,
future financial performance and other matters. These statements are based on
certain assumptions made by Medicis based on its experience and perception of
historical trends, current conditions, expected future developments and other
factors it believes are appropriate in the circumstances. Such statements are
subject to a number of assumptions, risks and uncertainties, many of which are
beyond the control of Medicis. Any such projections or statements include the
current views of Medicis with respect to future events and financial
performance. No assurances can be given, however, that these events will occur
or that such results will be achieved. Medicis cannot validate its assumptions
of the full impact on its business of the approval of competitive generic
versions of its core brands, or any future competitive product approvals that
may affect its brands. Also, there are a number of additional important factors
that could cause actual results to differ materially from those projected,
including the anticipated size of the markets, the availability of product
supply, the receipt of required regulatory approvals, the ability to realize
anticipated synergies and benefits of the Q-Med transaction, the risks and
uncertainties normally incident to the pharmaceutical industry, dependence on
sales of key products, the uncertainty of future financial results and
fluctuations in operating results, dependence on Medicis' strategy including the
uncertainty of license payments and/or other payments due from third parties,
the timing and success of new product development by Medicis or third parties,
product introductions and other risks described from time to time in Medicis'
SEC filings including its Annual Report on Form 10-K for the year ended June 30,
2004. There can be no assurance as to when or if any of the holders of the Notes
will have the right to convert or if the Notes will be converted, and what
impact the increase in the number of shares outstanding will have on its results
of operations. Forward-looking statements represent the judgment of Medicis'
management as of the date of this release, and Medicis disclaims any intent or
obligation to update any forward-looking statements.
NOTE: Full prescribing information for any Medicis prescription product is
available by contacting the Company. OMNICEF(R) is a registered trademark of
Abbott Laboratories, Inc. under a license from Fujisawa Pharmaceutical Co., Ltd.
RESTYLANE(R) is a registered trademark of HA North American Sales AB, a
subsidiary of Medicis Pharmaceutical Corporation. All other marks (or brands)
and names are the property of Medicis or its Affiliates.
(more)
Medicis
Summary Statements of Operations
--------------------------------
(in thousands, except per share data)
Three Months Ended Nine Months Ended
March 31, March 31,
------------------------------------- ---------------------------------------
2005 2004 2005 2004
------------------------------------- ---------------------------------------
Revenues $ 95,188 $ 81,839 $276,355 $ 215,767
Cost of sales 13,914 13,118 41,185 34,536
-------- -------- -------- ---------
Gross profit 81,274 68,721 235,170 181,231
Operating expenses:
Selling, general and administrative 31,868 28,793 96,327 87,907
Research and development 14,518(a) 3,084 60,934(b) 12,375(c)
Depreciation and amortization 6,054 4,707 16,276 11,872
-------- -------- -------- ---------
Total operating expenses 52,440 36,584 173,537 112,154
Operating income 28,834 32,137 61,633 69,077
Interest (income) expense, net (331) 335 (83) 449
Loss on early extinguishment of debt -- -- -- 58,660
Income tax expense 9,794 11,131 21,121 2,833
-------- -------- -------- ---------
Net income $ 19,371 $ 20,671 $ 40,595 $ 7,135
======== ======== ========= =========
Basic net income per common share $0.36 $0.37 $0.73 $0.13
======== ======== ========= =========
Diluted net income per common share $0.30 $0.31 $0.64 $0.12
======== ======== ========= =========
Shares used in basic net income per common share 54,251 56,042 55,506 55,198
Shares used in diluted net income per common share 69,773 73,164 71,489 58,569
Cash flow from operations $ 33,848 $ 37,446 $ 79,313 $ 77,428
- ------------------------------------------------------------------------------------------------------------------------------------
GAAP Net income (above) $ 19,371 $ 20,671 $ 40,595 $ 7,135
Special charge for R&D (tax-effected) 4,976(a) -- 27,830(b) 1,575(c)
Loss on early extinguishment of debt (tax-effected) -- -- -- 37,474
-------- -------- -------- ---------
Net income absent special charge $ 24,347 $ 20,671 $ 68,425 $ 46,184
Interest expense and associated bond offering
costs (tax-effected) 1,674(d) 1,666(d) 5,026(e) 5,143(e)
-------- -------- -------- ---------
"If-converted" net income absent special charge
and loss on early extinguishment of debt $ 26,021 $ 22,337 $ 73,451 $ 51,327
======== ======== ========= =========
Shares used in diluted net income per common
share 69,773 73,164 71,489 71,816
Diluted net income per common share $0.37 $0.31 $1.03 $0.71
======== ======== ========= =========
- ------------------------------------------------------------------------------------------------------------------------------------
(a) Reported R&D expenses include a special charge of $8.3 million ($5.0 million
tax-effected) relating to a research & development collaboration.
(b) Reported R&D expenses include a special charge of $44.6 million ($27.8
million tax-effected) relating to research & development collaborations.
(c) Reported R&D expenses include a special charge of $2.4 million ($1.6 million
tax-effected) relating to a research & development collaboration.
(d) To calculate diluted earnings per share, tax-effected net interest on the
2.5% and 1.5% contingent convertible notes and associated bond offering costs of
$1.7 million and $1.7 million are added back to GAAP net income for the three
months ended March 31, 2005 and 2004, respectively, and divided by shares used
in diluted net income per common share.
(e) To calculate diluted earnings per share, tax-effected net interest on the
2.5% and 1.5% contingent convertible notes and associated bond offering costs of
$5.0 million and $5.1 million are added back to GAAP net income for the nine
months ended March 31, 2005 and 2004, respectively, and divided by shares used
in diluted net income per common share. For GAAP diluted net income per common
share for the nine months ended March 31, 2004, the dilutive shares relative to
the convertible notes are not included as they are anti-dilutive.
Balance Sheets
--------------
At March 31, 2005 At June 30, 2004
----------------- ----------------
(unaudited)
Assets
Cash, cash equivalents & short-term investments $ 561,254 $ 634,040
Accounts receivable, net 48,004 47,858
Inventory, net 19,067 19,540
Other current assets 31,202 32,425
----------- -----------
Total current assets 659,527 733,863
Property and equipment, net 6,346 5,842
Intangible assets, net 329,497 331,144
Other assets 11,214 7,535
----------- -----------
Total assets $ 1,006,584 $ 1,078,384
=========== ===========
Liabilities and stockholders' equity
Current liabilities $ 87,013 $ 67,120
Contingent convertible senior notes 2.5% due 2032 169,155 169,157
Contingent convertible senior notes 1.5% due 2033 283,910 283,910
Deferred tax liability 4,891 2,894
Stockholders' equity 461,615 555,303
----------- -----------
Total liabilities and stockholders' equity $ 1,006,584 $ 1,078,384
=========== ===========
Working capital $ 572,514 $ 666,743
=========== ===========
# # #